14 November 2024 - NICE has published final evidence-based recommendations on the use of elafibranor (Iqirvo) for the treatment of adults with primary biliary cholangitis.

Elafibranor is recommended as an option for the treatment of patients with primary biliary cholangitis:

• In combination with ursodeoxycholic acid if the primary biliary cholangitis has not responded well enough to ursodeoxycholic acid
• As monotherapy if ursodeoxycholic acid cannot be tolerated

Elafibranor is only recommended if Ipsen provides it according to the commercial arrangement.

Read NICE technology appraisal guidance